Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Passes Above Two Hundred Day Moving Average – Here’s What Happened

Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.78 and traded as high as $5.76. Cumberland Pharmaceuticals shares last traded at $5.61, with a volume of 38,343 shares changing hands.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on CPIX. Wall Street Zen lowered Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Cumberland Pharmaceuticals Trading Down 0.7%

The company has a quick ratio of 0.79, a current ratio of 0.95 and a debt-to-equity ratio of 0.25. The company has a 50-day simple moving average of $4.26 and a two-hundred day simple moving average of $3.81.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). Cumberland Pharmaceuticals had a negative return on equity of 12.01% and a negative net margin of 17.60%.The firm had revenue of $9.13 million for the quarter, compared to analyst estimates of $8.50 million.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new stake in Cumberland Pharmaceuticals in the second quarter worth $34,000. Arrowstreet Capital Limited Partnership acquired a new stake in Cumberland Pharmaceuticals in the first quarter worth $66,000. Two Sigma Investments LP increased its position in Cumberland Pharmaceuticals by 16.5% in the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after buying an additional 5,326 shares during the period. Marshall Wace LLP acquired a new stake in Cumberland Pharmaceuticals in the fourth quarter worth $192,000. Finally, Geode Capital Management LLC increased its position in Cumberland Pharmaceuticals by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock worth $427,000 after buying an additional 5,653 shares during the period. 15.51% of the stock is owned by institutional investors and hedge funds.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.